Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 25 May 2018
At a glance
- Drugs LCL 161 (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
- Focus Adverse reactions
- 16 May 2018 Planned End Date changed from 1 Dec 2018 to 27 Jul 2019.
- 16 May 2018 Planned primary completion date changed from 27 Jul 2018 to 27 Jul 2019.
- 22 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.